Phillip H. Kuo, MD, PhD, Assesses Use of 177Lu-PSMA-617 in a Multidisciplinary Setting for Pretreated mCRPC


Phillip H. Kuo, MD, PhD, spoke about incorporating prostate-specific membrane antigen–PET imaging into multidisciplinary care for patients with metastatic castration-resistant prostate cancer.

Phillip H. Kuo, MD, PhD, professor of medical imaging, biomedical engineering, and medicine as well as member of the Graduate Faculty at The University of Arizona College of Medicine in Tucson, spoke with CancerNetwork® at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting about multidisciplinary care for patients with metastatic castration-resistant prostate cancer. He specifically focused on using prostate-specific membrane antigen (PSMA)–PET imaging, which was used in the the phase 3 VISION trial (NCT03511664) to identify patients with previously treated disease who were acceptable for randomization to 177Lu-PSMA-617 (Pluctivo) or standard of care treatment.1 The substudy aimed to determine if standardized uptake value (SUV) mean by 68Ga-PSMA-11 PET/CT imaging could be predictive of outcomes with 177Lu-PSMA-617, with results showing that the experimental therapy resulted in better overall survival vs the control arm consistently across groups.2


Prostate cancer care is already a very multidisciplinary space. The nuclear medicine component of it has already played big part for quite some time, not only from the diagnostic standpoint of, for example, the bone scans that have been around for decades, but even for palliative care. We had beta-emitting isotopes that many people may be familiar with like quadramet [Samarium (153Sm) lexidronam]. More recently, we had the first FDA-approved alpha-emitting therapy in radium [radium-223], which showed a 4-month improved survival in patients with bone metastases but no solid organ metastases. Now, the nuclear medicine team will be able to play an even bigger part in metastatic castrate-resistant prostate cancer.

This theragnostic paradigm shows the power of nuclear medicine that may be involved in patient selection with imaging, but also in the therapeutic arm with 177Lu-PSMA-617. In the VISION trial, they tried to get at least 4 cycles of therapy and then go to a maximum of 6 cycles if they showed a good response, importantly with tolerable adverse effects. What these results show are 2 things that might change practice. Routinely in practice, SUV mean is not reported out, so we may have to change our workflow to report it. Fortunately, there are artificial intelligence algorithms and software that are being rapidly developed that might allow us to do that on a routine basis as the standard of care so we can apply that SUV mean parameter to daily care to further personalize oncologic care. [For example, it may be evident that a certain] patient is going to do better than [having a 15.3-month overall survival as was demonstrated at the initial read-out of the VISION trial and may be at 21 months such as in those in the substudy within the highest standardized uptake value mean quartile]. Beyond just PSMA-PET scans, there are a lot of things that can factor into how well a patient is going to do [such as] their hemoglobin, the LDH [lactate dehydrogenase] values, and a lot of other things. We also have to take into account how many therapies they received and their bone marrow reserve. It’s always going to be a multidisciplinary decision with, of course, the patient at the center.


  1. Kuo P, Hesterman J, Rahbar K, et al. [68Ga]Ga-PSMA-11 PET baseline imaging as a prognostic tool for clinical outcomes to [177Lu]Lu-PSMA-617 in patients with mCRPC: A VISION substudy. J Clin Oncol. 2022;40(suppl 16):5002. doi:10.1200/JCO.2022.40.16_suppl.5002
  2. Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021;385(12):1091-1103. doi:10.1056/NEJMoa2107322

Related Videos
Financial constraints and a lack of education among some patients and providers must be addressed to improve the real-world use of certain prostate cancer therapies, says Neeraj Agarwal, MD.
Novel anti-PSMA monoclonal antibody rosopatamab is capable of carrying a bigger payload of radiation particles, which may potentially reduce doses for patients with prostate cancer, says Neeraj Agarwal, MD.
Findings from recent studies support the use of artificial intelligence-based tools in the context of radiation therapy for patients with localized prostate cancer, according to Neeraj Agarwal, MD.
Germline testing may elucidate important mutations in patients with metastatic prostate cancer who may be eligible to receive treatment with PARP inhibitors, according to Neeraj Agarwal, MD.
In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.
Artificial intelligence programs may help introduce new care strategies that minimize the risk of adverse effects in patients with prostate cancer, according to Wayne G. Brisbane, MD.
An artificial intelligence algorithm appears to create accurate focal treatment margins in patients with prostate cancer, according to Wayne G. Brisbane, MD.
Artificial intelligence may be useful in screening for prostate cancer in patients with elevated prostate specific antigen levels who have undergone MRI, according to Wayne G. Brisbane, MD.
Common adverse effects following treatment with lenvatinib plus pembrolizumab in the phase 3 CLEAR study include diarrhea, hypertension, and fatigue, according to Thomas E. Hutson, DO, PharmD, FACP.
Lenvatinib in combination with pembrolizumab appears to raise no new safety signals in patients with advanced clear cell renal cell carcinoma after 4 years of follow-up in the phase 3 CLEAR study.
Related Content